Summary of the Conference Call Company Overview - The conference focused on LENS Therapeutics, discussing their upcoming regulatory update and product launch plans for LENS100, a treatment for presbyopia [1][2]. Regulatory Updates - The PDUFA date for LENS100 is set for August 8, with positive feedback from the FDA during a recent late cycle review [2][4]. - No major or minor observations were noted by the FDA, indicating a smooth regulatory path towards approval [3][4]. Product Differentiation - LENS100 is the only presbyopia treatment utilizing aceclidine, which effectively creates a small pinhole pupil below two millimeters, enhancing near vision without significant side effects [5][6][8]. - In clinical trials, 71% of participants experienced at least three lines of near vision improvement, significantly outperforming competitors like Vuity [10][12]. - The product's efficacy profile shows a sustained effect, with 40% of participants maintaining improvement at ten hours post-application, compared to only 10% for Vuity [10][12]. Market Potential - The presbyopia market is estimated to exceed $3 billion, with 128 million presbyopes in the U.S. and 4 million new cases annually [13][14]. - The company anticipates a 6% penetration rate among presbyopes, leading to approximately 8 million long-term users [16][20]. - The pricing strategy is expected to be around $79 per prescription, similar to Vuity, which had a successful launch with 150,000 scripts sold [19][20]. Commercial Strategy - A sales force of 88 representatives has been established, primarily targeting optometrists, as they account for 80% of script sales in the presbyopia market [22][24]. - The marketing strategy will focus on digital channels, with a budget of $75 to $80 million for direct-to-consumer (DTC) advertising in the first year [39][67]. - The company plans to sample the product heavily to ensure consumer experience and retention, aiming for a higher refill rate than competitors [49][51]. Financial Outlook - LENS Therapeutics is well-funded, with expectations of reaching cash flow positivity by the PDUFA date, bolstered by a strong balance sheet and non-dilutive cash from licensing deals [65][66]. - The projected commercial spend post-launch is approximately $100 million, with a focus on maintaining a lean operational structure [67][68]. Intellectual Property and Supply Chain - The product is protected by a robust IP portfolio, including five years of data exclusivity upon approval and multiple granted patents [61][62]. - The supply chain is designed to be efficient, with API production in the U.S. and fill-finish operations in Germany, ensuring a duty-free status [55][56]. Future Growth and Licensing - The company is exploring opportunities for expansion through mergers and acquisitions, aiming to build a broader portfolio around LENS100 [70][71]. - Licensing agreements are already in place for markets in China and Southeast Asia, with plans to expand into Europe and other regions through partnerships [73][74]. Conclusion - LENS Therapeutics is positioned for a successful product launch with a strong regulatory outlook, differentiated product offering, and a comprehensive commercial strategy aimed at capturing a significant share of the presbyopia market [1][20][70].

Corporate Presentation May 2025 NASDAQ: LENZ Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," believes," "continues," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predict ...

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3, 2025Location: Chicago, ILFormat: Mana ...

Summary of the Conference Call Company and Industry - The conference call discusses **LNZ100**, a treatment for **presbyopia**, a condition affecting near vision, developed by a **biotech company**. The FDA action date for LNZ100 is set for **August 8** of the current year, with a planned launch in **Q4**. Core Points and Arguments - **FDA Approval Confidence**: The company expresses strong confidence in the FDA approval timeline, stating that interactions with the FDA are frequent and productive, with the review team fully in place [3][4][6]. - **Commercial Readiness**: The company is actively preparing for the product launch, including hiring sales representatives and producing commercial-scale product batches. Final packaging awaits FDA approval [5][12][15]. - **Market Dynamics**: The presbyopia market is described as **promotion-sensitive**, with a significant number of potential patients (approximately **40 million**) presenting themselves to optometrists monthly. The company plans to implement direct-to-consumer (DTC) marketing strategies to double patient engagement [30][32][34]. - **Product Differentiation**: LNZ100 is positioned as a superior product compared to competitors like **Vuity**, with claims of better efficacy and longer duration of effect. The company emphasizes its unique mechanism of action that avoids negative impacts on distance vision [24][29][75]. - **Pricing Strategy**: The anticipated price for LNZ100 is around **$80 per month**, similar to other cash-pay products, which allows for flexible promotional strategies [37][70]. - **Long-term Market Potential**: The total addressable market (TAM) for LNZ100 is estimated at **$3 billion** in the U.S. alone, with a focus on targeting specific patient segments, including contact lens wearers and those who have undergone LASIK [42][66]. - **Intellectual Property**: The company holds a robust patent portfolio with protections extending to **2034** and beyond, ensuring a long product lifecycle without traditional generic competition [76][78]. Other Important Content - **Sales Strategy**: The sales force will primarily target optometrists (80%) rather than ophthalmologists, which is a shift from competitors' strategies. The company plans to leverage a strong sales team with significant eye care experience [58][85]. - **Patient Engagement**: The company has already engaged with optometrists and patients in clinical trials, generating positive testimonials that are expected to drive word-of-mouth marketing [39][41]. - **Economic Resilience**: The company believes it will be insulated from economic downturns, as consumers prioritize products that enhance their quality of life, similar to contact lenses and aesthetic treatments [70][72]. - **Future R&D Focus**: While the immediate focus is on the launch of LNZ100, the company envisions expanding its portfolio through mergers and acquisitions in the ophthalmology space once it achieves cash flow breakeven [82]. This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic approach to launching LNZ100 and its positioning within the presbyopia treatment market.

Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net salesSAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast A ...

LENZ Therapeutics (LENZ) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Dan Chevallard - CFOEvert Schimmelpennink - President, CEO, Secretary & DirectorShawn Olsson - Chief Commercial OfficerYigal Nochomovitz - DirectorDenis Reznik - Senior Equity Research Associate Conference Call Participants Stacy Ku - AnalystPavan Patel - AnalystLachlan Hanbury-Brown - Biotech Equity Research AnalystMatthew Caufield - VP - Senior Healthcare Analyst Operator afternoon, ladies and gentlemen, and welco ...

LENZ Therapeutics (LENZ) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 afternoon, ladies and gentlemen, and welcome to the LENS Therapeutics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. Following prepared remarks from management, As a reminder, this call is being recorded. At this time, I would like to turn the call over to Dan Chevillard, Chief Financial Officer. Please go ahead. Speaker1 Thank you. Good afternoon an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-40532 _________________________ LENZ THERAPEUTICS, INC. (Exact n ...

Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 hiring actively underway for 88 sales representatives, targeted for completion by July 1, 2025. A replay of the Commercial Day presentations is available in the Events section of the Investor Relations page on the LENZ Therapeutics website at www.LENZ-tx.com. Cash, cash equivalents ...

Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" ...